Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARDIOMEUSE trial of rimonabant in daily practice
NL-OMON20796Recruiting
- Sponsor
- Maastricht University
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of rimonabant in type 2 diabetes mellitus (T2DM), impaired fasting glucose (IFG) and cardiometabolic risk (CMR) (4 arms), sponsored by Maastricht University. Primary endpoints: Waist circumference, Plasma glucose and 2 more. Started Sep 2006; status: recruiting.
02
Drugs
rimonabant
03
Conditions
type 2 diabetes mellitus (T2DM)impaired fasting glucose (IFG)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on NL-OMON20796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20796.